• June 25, 2015

    Press Release Spotlight

    Stealth BioTherapeutics Announces Results in Ocuvia Diabetic Macular Edema Study: The ReVIEW Trial

    Read the full article

    Promising data highlighted during Mitochondrial Science and Medicine Series BOSTON – June 25, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced results from its ReVIEW study of Ocuvia in diabetic macular edema (DME) patients. The results were presented in New York City at Stealth’s second Mitochondrial… Continue Reading >

    Read the full article
  • June 22, 2015

    Press Release Spotlight

    Stealth BioTherapeutics Presents at 2015 United Mitochondrial Disease Foundation National Symposium

    Read the full article

    Orphan mitochondrial disease program highlighted during annual meeting Boston, MA – June 22, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, provided a development update for its investigational drugs, Bendavia and Ocuvia, and announced future clinical plans for its orphan mitochondrial disease program at the 2015 United Mitochondrial… Continue Reading >

    Read the full article
  • May 26, 2015

    Press Release Spotlight

    Stealth BioTherapeutics Announces Positive Results in Bendavia Heart Failure Study: The PREVIEW Trial

    Read the full article

    Promising findings highlighted at European Society of Cardiology Heart Failure Congress Boston, MA – May 26, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced positive heart failure results from its PREVIEW study showing Bendavia improved cardiac function for patients. The results were presented at the European… Continue Reading >

    Read the full article
  • April 27, 2015

    Press Release Spotlight

    Stealth BioTherapeutics Expands Ocuvia’s Clinical Development into Rare Mitochondrial Optic Neuropathies

    Read the full article

    Ocuvia is one of the first investigational drugs with potential to treat inherited optic neuropathies common in over 20 genetic mitochondrial diseases Boston, MA – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for mitochondrial dysfunction, today announced expansion of its ophthalmology program with FDA granting a Type B meeting for inherited optic… Continue Reading >

    Read the full article

Stealth BioTherapeutics Announces Results in Ocuvia Diabetic Macular Edema Study: The ReVIEW Trial

Promising data highlighted during Mitochondrial Science and Medicine Series BOSTON – June 25, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced results from its ReVIEW study of Ocuvia in diabetic macular edema (DME) patients. The results were presented in New York City at Stealth’s second Mitochondrial… Continue Reading >

Stealth BioTherapeutics Presents at 2015 United Mitochondrial Disease Foundation National Symposium

Orphan mitochondrial disease program highlighted during annual meeting Boston, MA – June 22, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, provided a development update for its investigational drugs, Bendavia and Ocuvia, and announced future clinical plans for its orphan mitochondrial disease program at the 2015 United Mitochondrial… Continue Reading >

Stealth BioTherapeutics to Present at Jefferies 2015 Healthcare Conference

Presentation will be on Monday, June 1st, 2015 at 10:30 AM ET Boston, MA – May 27, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced that Travis Wilson, Chief Executive Officer, will present a corporate overview and development update at the Jefferies 2015 Healthcare Conference in… Continue Reading >

Stealth BioTherapeutics Announces Positive Results in Bendavia Heart Failure Study: The PREVIEW Trial

Promising findings highlighted at European Society of Cardiology Heart Failure Congress Boston, MA – May 26, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced positive heart failure results from its PREVIEW study showing Bendavia improved cardiac function for patients. The results were presented at the European… Continue Reading >

Stealth BioTherapeutics Expands Ocuvia’s Clinical Development into Rare Mitochondrial Optic Neuropathies

Ocuvia is one of the first investigational drugs with potential to treat inherited optic neuropathies common in over 20 genetic mitochondrial diseases Boston, MA – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for mitochondrial dysfunction, today announced expansion of its ophthalmology program with FDA granting a Type B meeting for inherited optic… Continue Reading >